All In Biotech

NDA 021398 · Abbvie

Combigan

Brimonidine Tartrate, Timolol Maleate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Oct 30, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

177

44 Phase 3, 5 recruiting

FAERS reports

6,644

2,704 serious, 318 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 17, 2026.

COMBIGAN ® is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. COMBIGAN is a combination of brimonidine tartrate, an alpha-adrenergic receptor agonist, and timolol maleate, a beta-adrenergic receptor inhibitor, indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP. The IOP-lowering of COMBIGAN dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution, 0.2% dosed three times per day. ( 1 )

Mechanism: COMBIGAN is comprised of two components: brimonidine tartrate and timolol. Each of these two components decreases elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic nerve damage. COMBIGAN is a relatively selective alpha-2 adrenergic receptor agonist with a non-selective beta-adrenergic receptor inhibitor. Both brimonidine and timolol...

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • COMBIGAN · BRIMONIDINE TARTRATE 0.2%; TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.

All 177 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ocular hyperaemia544
  • eye irritation532
  • eye pain481
  • fatigue383
  • drug ineffective365
  • vision blurred341
  • off label use297
  • intraocular pressure increased295
  • dizziness270
  • eye pruritus255
  • headache246
  • diarrhoea215

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20062
200713
200840
2009338
2010193
2011224
2012158
2013181
2014213
2015479
2016695
2017602
2018611
2019555
2020561
2021453
2022369
2023305
2024257
2025266
2026128

Recalls

2 FDA enforcement reports for this application.

  • Mar 19, 2019 · Class II · Terminated

    cGMP Deviations

  • Oct 19, 2017 · Class III · Terminated

    Failed Impurities/Degradation Specifications.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Combigan (Brimonidine Tartrate/Timolol)

2024 spending

$162M

Beneficiaries

114,398

465,280 claims

Per beneficiary

$1,418

$38.75 per unit

View as table
YearSpending
2020$379,353,449
2021$392,681,109
2022$291,993,108
2023$232,102,953
2024$162,254,896

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 313 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.